Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Amen to that!
I am not sure I understand how that can be done. Raising $200 would be great, but how?
She is 0% correct in her PT predictions with HGEN. It only makes sense that she put the PT lower than the current price by a penny. I interpreted it as her padding the stats.
Jay, you really struck a nerve, I see. No reason to stop now!
Such potential here. This will not stay below $1 long.
TLD just needs to reinforce Live Air and EUA will be undeniable. The pathway will clear to other areas. Would be fantastic to get BLA within 18 months.
What are you talking about? Is this morning “old” for you?
Fantastic news! What could have triggered the NIH to include Humanigen in on this study?
Unfortunate and costly, yes. But I admit, I was able to accumulate a good deal more shares since September.
Taking dilution into account, there should be no reason HGEN doesn’t get back into the $20’s with good top line data and on the verge of EUA, MHRA, and CMA.
Statistically it would be difficult to not be positive data. And with the NIH expanding the trial, obviously they saw something they liked.
It’s simply a matter of time.
Much is hinging on the ACTIV-5 data. We should know soon whether Lenz is the backbone to the Covid fight. I am looking forward to finally seeing the results.
Thanks Don. We are close. Anxious to finally see TLD.
No. It sounds like a real mess.
We can probably assume Avid Biosciences is no longer a manufacturing option.
445k trade in AH and no one notices?
Good speculation. But I imagine the company may want to time quarterly earnings so any insider purchases have a more direct result on opex. The last purchases didn’t have much staying power. As a result, the price was walked back down. They may be better off releasing earnings on the 12th, allow two days, and start pelting the market with buys.
We’ll see how interested Dale is in keeping those options in the money.
Funny, you were saying that same thing when the stock price was $3. Either you are a bot or an idiot.
Jay, I think the slide is to show an example of the annual number of deaths related to an endemic rather than insinuate Lenz can help treat some cases of influenza. Although, there is a likelihood of some flu cases going the route of cytokine storm - not that I have any basis to make that claim.
Correct. I should have clarified that it may get interesting when Dale can no longer buy.
It may be more interesting when he stops buying.
Dale doing some more buying.
Good call Don. Insiders are buying after a long blackout period.
Check. Insider buying next.
It is interesting timing - both date and time - for releasing earnings. Also, notice the headquarters changed to NJ. The CA office is now only a satellite office.
My presumption would be the crew is going to buy shares on the open market. And in the coming months we will learn of the suitor involved in acquiring Humanigen. Pure speculation. But why move the headquarters otherwise?
At the same time, the UK has now become the first major western economy to end Covid restrictions. It will be interesting to see if others will follow.
When the same song plays over and over again they call it a broken record. At what point does the jukebox eject the record?
The narrative of Dale selling while some poor soul was left as a bag holder is truly getting old. Amazing how the narrator appears to the rest of us.
Sorry to hear EB. Be strong. Best of luck with a positive outcome.
Stockpiling orders would be considered material and need to be public, correct?
Interesting. I wonder how that came about considering the situation between Humanigen and Eversana since the FDA postponed the EUA.
Same in my area. Hospitals are at capacity. And, according to the experts, we have yet to see the forthcoming surge. A good solution to assist hospitals is to add a treatment that avoids long hospitalization. Anyone know of such a thing?
Reeks is an understatement.
Humanigen will succeed despite the resistance.
Who do you think the buyer is?
Are we at the low of 2022 so I can buy more? This was an unnecessary drop and I figure CDMO will be back to $30 in short time.
I agree. Activ 5 data will gain an EUA, MHRA and potentially a CMA with Europe. My concern is inventory and how quickly it can be made. If the US and UK both approved Lenz simultaneously, I don’t think 100k treatments is enough. Having shut down production after September, what would it take to ramp it up to match demand?
Sounds like a desperate plea. I am buying more HGEN because of it.
Excellent point Jay! The product is so easily forgotten about until approval is acquired.
Leave it to corporalagarn to finally bring some logic to the HGEN board for those who cannot stop whining about Dale selling! Thank you.
Good perspective on the situation. As Cameron indicated in the company update, it is unknown why the EUA was declined. The FDA has not provided sufficient feedback or clarification. Was it the trial size? Was it effectiveness vs. safety? Was it cost of the treatment? Something else deeper in the data?
The company received a vague, template response. It’s easy to make negative arguments (as many trolls do) when information is vague.
My hope is the Type-B meeting opens up the dialogue and gets the company the specific information needed to push an approval. Big Pharmas have an advantage over small companies because they have contacts inside the FDA (former employees or previous contacts from other meetings) they can rely on. Seems to be a major disadvantage for small companies - despite how well the tech is.
All this gives the appearance of political influence that BP has on the FDA. Right or wrong, it is happening. But, I believe the FDA will do the right thing eventually. The question becomes how much damage will be done to the business. Supply chain disruption has already taken place. Available doses of lenzilumab will be less because of production halt. We’re already incurring an increase in available shares. How much more?
Having the peer review in hand and probably additional data that will be presented to the MHRA and FDA might justify his conviction. We’ll never know if those people would have died or not, but he can definitely say they would not have died from lenzilumab. Any safety doubt is removed.
Great news Cheynew! Hope you are well.